TY - JOUR
T1 - Serum biomarkers identification by mass spectrometry in high-mortality tumors
AU - Tessitore, Alessandra
AU - Gaggiano, Agata
AU - Cicciarelli, Germana
AU - Verzella, Daniela
AU - Capece, Daria
AU - Fischietti, Mariafausta
AU - Zazzeroni, Francesca
AU - Alesse, Edoardo
PY - 2013
Y1 - 2013
N2 - Cancer affects millions of people worldwide. Tumor mortality is substantially due to diagnosis at stages that are too late for therapies to be effective. Advances in screening methods have improved the early diagnosis, prognosis, and survival for some cancers. Several validated biomarkers are currently used to diagnose and monitor the progression of cancer, but none of them shows adequate specificity, sensitivity, and predictive value for population screening. So, there is an urgent need to isolate novel sensitive, specific biomarkers to detect the disease early and improve prognosis, especially in high-mortality tumors. Proteomic techniques are powerful tools to help in diagnosis and monitoring of treatment and progression of the disease. During the last decade, mass spectrometry has assumed a key role in most of the proteomic analyses that are focused on identifying cancer biomarkers in human serum, making it possible to identify and characterize at the molecular level many proteins or peptides differentially expressed. In this paper we summarize the results of mass spectrometry serum profiling and biomarker identification in high mortality tumors, such as ovarian, liver, lung, and pancreatic cancer.
AB - Cancer affects millions of people worldwide. Tumor mortality is substantially due to diagnosis at stages that are too late for therapies to be effective. Advances in screening methods have improved the early diagnosis, prognosis, and survival for some cancers. Several validated biomarkers are currently used to diagnose and monitor the progression of cancer, but none of them shows adequate specificity, sensitivity, and predictive value for population screening. So, there is an urgent need to isolate novel sensitive, specific biomarkers to detect the disease early and improve prognosis, especially in high-mortality tumors. Proteomic techniques are powerful tools to help in diagnosis and monitoring of treatment and progression of the disease. During the last decade, mass spectrometry has assumed a key role in most of the proteomic analyses that are focused on identifying cancer biomarkers in human serum, making it possible to identify and characterize at the molecular level many proteins or peptides differentially expressed. In this paper we summarize the results of mass spectrometry serum profiling and biomarker identification in high mortality tumors, such as ovarian, liver, lung, and pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84916877458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84916877458&partnerID=8YFLogxK
U2 - 10.1155/2013/125858
DO - 10.1155/2013/125858
M3 - Review article
C2 - 23401773
AN - SCOPUS:84916877458
SN - 2090-2166
VL - 2013
JO - International Journal of Proteomics
JF - International Journal of Proteomics
M1 - 125858
ER -